Charles River Laboratories account plan
Patients Animal Planet People
At a glance
Charles River Laboratories is a non-clinical drug development partner: research models, safety testing and QC; FY2025 revenue $4.02 billion.
Charles River Laboratories (NYSE: CRL), based in Wilmington, Massachusetts, is a full-service, non-clinical drug development partner. It supplies research models, discovery and regulated safety assessment services and manufacturing quality-control testing to pharma, biotech, medical device and other clients, from over 120 sites in over 20 countries. FY2025 revenue was $4,015.4 million (down 0.9%), with GAAP operating income of $25.2 million after impairments and a net loss to shareholders of $144.3 million. It had approximately 19,700 employees at December 27, 2025. Birgit Girshick succeeded James C. Foster as CEO in May 2026.
Business units
Discovery and Safety Assessment (DSA)
59.8% of FY2025 revenue ($2,402.9 million)Drug discovery, toxicology, pathology, safety pharmacology and bioanalysis for clients from target identification to non-clinical development. Q3 2026 revenue was $596.3 million with 5.9% organic growth, a net book-to-bill of 1.09x and a backlog of $2.03 billion. Shannon Parisotto is the executive officer for DSA.
Research Models and Services (RMS)
21.1% of FY2025 revenue ($846.1 million)Purpose-bred rodents and large research models, insourcing (CRADL vivarium space), genetically engineered models and animal diagnostics. Cell Solutions was sold in May 2026. Q3 2026 revenue was $207.5 million, down 0.6% organically, with China growing and North American small models weaker.
Manufacturing Solutions
19.1% of FY2025 revenue ($766.4 million)Microbial Solutions (Endosafe endotoxin testing, Celsis, Accugenix) and Biologics Testing; the cell and gene therapy CDMO was sold in May 2026. Q3 2026 revenue was $178.9 million with 7.4% organic growth and a 38.6% margin.
Strategic priorities
- Pathway to Purpose strategy
- Presented at the September 24, 2026 Investor Day: modernise the company, strengthen the scientific portfolio, and deliver a client-centric approach.
- Create the Future savings
- Over $300 million of cumulative savings from 2027 through 2030 through simpler processes, automation, digital enablement and AI-assisted tools, on top of about $300 million cumulative annualized savings by end-2026; 500 initiatives are under way.
- Grow bioanalysis
- Bioanalysis revenue is expected to grow at a high-single-digit CAGR to approximately $450 million in 2030, with five organic capacity expansions and the Frontage acquisition.
- 2030 financial targets
- 5%-7% organic revenue CAGR for 2027-2030, a non-GAAP operating margin of about 24% and low-double-digit non-GAAP EPS CAGR.
- Secure NHP supply
- With K.F. Cambodia and Noveprim, roughly 80% of estimated NHP usage is covered by the company's own farms.
- Simplify the portfolio
- Divest non-core assets of about 7% of 2025 revenue (done in May 2026) and reinvest in the core through acquisitions, partnerships and internal investment.
Latest results
In Q3 2026 (quarter ended September 26, 2026) revenue was $982.7 million, down 2.2% reported because of the May 2026 divestitures, but organic growth was 4.7% against an outlook of 1%-3%. GAAP operating income rose to $202.6 million (20.6% margin vs 13.3%) and non-GAAP EPS was $3.09, up 27.2%. DSA net bookings rose 32% to $652 million and backlog reached $2.03 billion. The company raised 2026 guidance to organic growth of at least 1.5% and non-GAAP EPS of $11.35-$11.55, and expects a gradual improvement in 2027.
Investments and deals
- Frontage bioanalysis and DMPK acquisition
- Agreed November 9, 2026: Frontage's Exton, Pennsylvania operations for approximately $470 million in cash plus up to $75 million of contingent payments, approximately 340 employees, closing expected in the first half of 2027.
- K.F. Cambodia NHP supplier
- Assets acquired January 14, 2026 at a preliminary price of $507.3 million, vertically integrating NHP supply for DSA.
- PathoQuest
- Remaining 79% bought on April 17, 2026 for $67.4 million: next-generation sequencing for biologics quality control, reported in Manufacturing.
- Divestitures
- European Discovery Services sold to IQVIA for $126.4 million (May 22, 2026); CDMO and Cell Solutions sold to GI Partners (May 6, 2026).
- Automation and Apollo platform
- A fully automated Endosafe cartridge suite increased production capacity by 14%; the Apollo cloud platform serves more than 18,000 client users.
Challenges and risks
- New approach methodologies
- The FDA's April 2025 plan to reduce animal testing and the U.K. roadmap to phase it out could reduce demand for some products and services.
- Weak RMS demand
- Academic and government clients are nearly 40% of RMS revenue; CRADL has not returned to growth because new biotech starts have not recovered.
- Pricing pressure
- Discounting is being reduced only modestly, with no major benefit expected before the second half of 2027.
- Impairments and portfolio losses
- 2025 included a $165.0 million Biologics Solutions goodwill impairment; the CDMO and Cell Solutions sale generated $181.7 million of losses over nine months of 2026.
- Biotech and government funding
- Demand depends on biotech funding and government R&D funding, which the 10-K names as key risks.
What leadership says
“Our focus is to simplify the company and move faster, invest where we can win, and continue to lead as the scientific partner of choice for the critical work that our clients do.”
“The planned acquisition accelerates our strategy to expand our bioanalysis capabilities and enhance our offering in an attractive, high-growth market.”
“we view AI as an enabling technology to support our work over a long term and to complement it, but we do not see it as a disruptor.”
“We have currently enough supply to meet our long-range financial targets”
Where a supplier can help
- Automation and digitisation for Create the Future
- The savings programme relies on automation, digital enablement and AI-assisted tools; vendors of lab automation and workflow software fit directly.
- Bioanalysis capacity build-out
- Five organic bioanalysis expansions and the Frontage integration create needs for lab equipment, facilities work and integration services.
- Procurement and global business services
- Procurement synergies, global business services and real-estate rationalisation are named savings levers, opening doors for outsourcing and procurement partners.
- NAMs and in vitro testing
- Investment in in vitro testing and NAMs such as virtual control groups needs data, software and assay technology partners.
- Client-facing digital tools
- Expanding the Apollo platform to more clients and segments points to demand for e-commerce, data and client portal technology.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Charles River Laboratories?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Annual Report on Form 10-K for fiscal year 2025 (ended December 27, 2025)
- Charles River Laboratories is a full-service, non-clinical drug development partner: research models, discovery and regulated safety assessment, and manufacturing quality-control testing, operating in over 120 sites and over 20 countries with approximately 19,700 employees.
- FY2025 revenue was $4.02 billion, down 0.9% from $4.05 billion; DSA is 59.8% of revenue, RMS 21.1%, Manufacturing 19.1%. No single client exceeded 4% of revenue.
- GAAP operating income collapsed to $25.2 million (0.6% margin, vs 5.6%) on a $165.0 million Biologics Solutions goodwill impairment and about $211.0 million of intangible impairments (Cell Solutions, CDMO Gene Therapy); net loss to shareholders was $144.3 million.
- Demand stabilised in 2025: large biopharma bookings improved early in the year, small and mid-sized biotech improved in the second half; DSA backlog stood at $1.9 billion vs $2.0 billion a year earlier.
- Board strategic review (November 2025): strengthen the core through acquisitions, partnerships and internal investment, divest non-core assets worth about 7% of 2025 revenue, drive efficiency, disciplined capital deployment; about 12 more sites to close or consolidate over two years.
- Cost actions are expected to yield about $300 million of cumulative annualized savings by the end of 2026 (more than $175 million benefited 2025); restructuring charges were $99.8 million.
- Supply-chain integration: K.F. (Cambodia) NHP assets bought in January 2026 for $510.0 million; option exercised on the remaining 79% of PathoQuest for EUR 51.6 million.
- Key risks: non-human primate supply, NAMs and FDA's April 2025 plan to reduce animal testing, biotech funding and government R&D funding, further impairments, debt ($2,116.5 million under the revolver and senior notes).
- Leadership: James C. Foster (CEO since 1992) retires on May 5, 2026; COO Birgit Girshick appointed next CEO; Michael Knell interim CFO since October 2025.
- Quarterly Report on Form 10-Q for Q3 2026 (quarter ended September 26, 2026)
- Q3 2026 revenue was $982.7 million, down 2.2% reported (nine months: $2,982.6 million, down 1.3%), reflecting the May 2026 divestitures; regulated safety assessment revenue rose $33.5 million.
- Q3 operating income rose to $202.6 million (20.6% margin vs 13.3%); net income to shareholders was $333.1 million, boosted by a $201 million tax benefit from reversing a reserve after a foreign tax law change.
- Segments, Q3: DSA $596.3 million (28.9% margin), RMS $207.5 million (19.9%), Manufacturing $178.9 million (35.7%) after the CDMO sale.
- Portfolio reshaped in 2026: K.F. Cambodia NHP supplier bought ($507.3 million preliminary price), PathoQuest 79% bought for $67.4 million; certain European Discovery Services businesses sold to IQVIA for $126.4 million; CDMO and Cell Solutions sold to GI Partners (loss of $181.7 million over nine months).
- Demand is improving: the DSA backlog rose to $2.0 billion from $1.9 billion at year-end on more biotech funding and global biopharma reinvesting in early-stage pipelines.
- The new Create the Future program targets more than $300 million of incremental savings between 2027 and 2030, on top of about $300 million cumulative annualized savings by end-2026.
- Nine-month operating cash flow fell to $474.9 million (from $590.1 million); $300.0 million of buybacks, $700.0 million left on the authorization.
- Q3 2026 earnings call transcript
- First call after the September 2026 Investor Day under CEO Birgit Girshick: Q3 organic growth of 4.7% (outlook was 1%-3%), "the highest level since the second quarter of 2023"; non-GAAP EPS $3.09, up 27.2%.
- DSA organic growth 5.9% on NHP studies and bioanalysis (BioA); net book-to-bill 1.09x, the fourth quarter in a row above 1x; net bookings up 32% to $652 million; backlog $2.03 billion.
- Manufacturing grew 7.4% organically after the CDMO sale, with margin at 38.6%; RMS declined 0.6% as academic and government clients are "nearly 40%" of RMS revenue.
- 2026 guidance raised: organic growth of at least 1.5%, non-GAAP EPS $11.35-$11.55; 2027 to improve gradually, with 5%-7% growth targeted from 2028.
- Strategy "Pathway to Purpose": simplify and move faster, invest where it can win; Create the Future targets over $300 million of savings over four years; 500 initiatives under way.
- Pricing: discounts are being reduced, but no revenue benefit is expected before at least the second half of 2027.
- Internal farms cover about 80% of estimated NHP usage; five bioanalysis capacity expansions are under way and M&A in bioanalysis is of interest.
- On AI: Girshick sees AI as a tailwind that brings more programs into regulated validation and safety testing, with "no difference" in dollars per program.
- Q4 and full-year 2025 earnings call transcript (2026 guidance, CEO transition)
- James C. Foster's final earnings call after more than thirty years as CEO; COO Birgit Girshick, CEO from the May 2026 annual meeting, gave the 2026 guidance. Glenn Coleman joins as CFO on April 6 and Carrie Daley as Chief Legal Officer on March 30.
- 2025: revenue $4,020,000,000, down 1.6% organically; Q4 $994,200,000, down 2.6%; full-year operating margin 19.8%; EPS $10.28 vs $10.32.
- Demand turning: Q4 DSA net book-to-bill 1.12x (from 0.82x in Q3) on $665,000,000 of net bookings, driven by biotech after record funding of $28,000,000,000 in Q4; DSA backlog $1,860,000,000.
- 2026 guidance: organic revenue from down 1% to at least flat; operating margin up 20 to 50 basis points; non-GAAP EPS $10.70-$11.20; return to organic growth expected in the second half.
- K.F. Cambodia acquisition to add about $0.25 to 2026 EPS and more than 100 basis points to DSA margin; Charles River will own and source most future NHP needs internally (with Noveprim).
- At least $100,000,000 of incremental cost savings in 2026; divestitures of about 7% of 2025 revenue to be completed in 2026; focus on debt repayment and "dry powder" for M&A (bioanalysis, geographic expansion).
- On AI, Foster: "we do not see it as a disruptor"; NAMs and AI are a gradual, longer-term evolution, especially in regulated safety assessment.
- 2026 Investor Day press release: Pathway to Purpose strategy and 2030 targets
- At its September 24, 2026 Investor Day, CEO Birgit Girshick presented "Pathway to Purpose", a refreshed strategy built on three initiatives: modernise the company, strengthen the scientific portfolio, and deliver a customized client-centric approach.
- Create the Future program: over $300 million of cumulative savings from 2027 through 2030 through simpler processes, automation, digital enablement and AI-assisted tools.
- Priority investment areas are bioanalysis, in vitro testing and related solutions; bioanalysis revenue is expected to grow at a high-single-digit CAGR to approximately $450 million in 2030.
- Apollo cloud platform serves more than 18,000 client users and now covers Manufacturing Solutions clients.
- 2030 targets: 5%-7% organic revenue CAGR 2027-2030, non-GAAP operating margin of about 24% (vs 21.0%-21.3% guided for 2026), low-double-digit non-GAAP EPS CAGR.
- 2026 revenue and non-GAAP EPS expected at the upper ends of the ranges (0%-1% organic growth; $11.15-$11.45).
- Press release: Charles River to acquire Frontage's bioanalysis and DMPK businesses
- On November 9, 2026 Charles River agreed to acquire Frontage Holdings' bioanalysis and DMPK operations in Exton, Pennsylvania for approximately $470 million in cash, plus up to $75 million of contingent payments; closing expected in the first half of 2027.
- The two Exton sites cover approximately 150,000 square feet, employ approximately 340 people and include a CLIA-certified central laboratory; they mainly serve clinical development programs.
- The acquired businesses were approximately 40% of Frontage's 2025 revenue of $256.7 million and will be reported in DSA.
- Rationale: expand clinical bioanalysis (today approximately 15% of Charles River's bioanalysis revenue) in a market expected to grow from approximately $6 billion in 2026 to approximately $8 to $9 billion in 2031.
- Structure: a consortium with Tigermed and Frontage chairman Dr. Song Li takes Hong Kong-listed Frontage private, then splits it; neutral to non-GAAP EPS in 2027 and accretive thereafter; financed with the credit facility and cash.
Questions about Charles River Laboratories
What does Charles River Laboratories do?
It supports drug development before clinical trials: research models, discovery and safety assessment services, and quality-control testing for drug manufacturing.
What is Charles River's revenue?
FY2025 revenue was $4,015.4 million; Q3 2026 revenue was $982.7 million.
How many employees does Charles River have?
Approximately 19,700 employees at December 27, 2025.
Who leads Charles River Laboratories?
Birgit Girshick has been CEO since May 2026, succeeding James C. Foster; Glenn Coleman is EVP and CFO.
What is Charles River's strategy?
Pathway to Purpose: modernise operations through the Create the Future savings programme, invest in bioanalysis and in vitro testing, and serve clients with a client-centric approach, targeting 5%-7% organic growth from 2027 to 2030.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)